Disc Medicine (IRON) Director Kevin Bitterman Sells $2M of Stock
Key Points
- Disc Medicine, Inc. Director Kevin Bitterman sold 25,519 shares on October 21, 2026, valued at approximately $2,047,389 under a pre-arranged plan.
- After the trade, Kevin Bitterman indirectly holds 12,991 $IRON shares, down 66.27% from before the trade.
- The stock recently traded around $79.48, sitting well above its 50-day and 200-day moving averages ahead of the November 5, 2026 earnings report.
- Major Wall Street firms including Wells Fargo and BMO Capital recently raised their price targets on the clinical-stage biotechnology company.
Get Disc Medicine text alerts
We text you when insiders, Congress, analysts or big funds move on $IRON.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Disc Medicine, Inc. alert may contain errors. Disclosures
Disc Medicine, Inc. Director Kevin Bitterman sold 25,519 shares of the company on October 21, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
IRON
Disc Medicine, Inc.
Kevin Bitterman vs. the S&P 500
Hypothetical returns from Kevin Bitterman's disclosed trades, not real profit or advice. How we model this.
Inside Kevin Bitterman's Disc Medicine Trade
The planned sale was executed at a price of $80.23 per share, totaling roughly $2,047,389. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the trade, Bitterman directly holds 12,991 shares, which is a 66.27% reduction in his personal holdings. On the day of the transaction, the stock closed at $76.00.
Other Institutional Activity in Disc Medicine
Large funds continue to adjust their positions in the biotechnology firm. Baker Bros. Advisors grew its holdings by 12,607 shares, ending with 349,657 shares worth about $25,573,913. Vestal Point Capital, LP grew its stake by 850,005 shares, or 121.4%, finishing with 1,550,000 shares valued at $117,800,000. Meanwhile, RA Capital Management, L.P. held steady with 2,450,221 shares worth $186,216,796, and Atlas Venture Life Science Advisors, LLC kept its holdings at 1,513,875 shares valued at $115,054,500.
Disc Medicine, Inc. Stock Holds Steady
The shares recently traded around $79.48 as of October 21, 2026, putting them up about 4.6% since that day's close. The stock trades comfortably above its 50-day moving average of $71.57 and its 200-day moving average of $70.66. It sits 20.1% below its 52-week high of $99.50 and up 98.7% from its 52-week low of $40.00.
Recent Earnings
The company reported a trailing-twelve-month loss with earnings per share at -$6.58 and a return on equity of -39.1%. The next earnings update is scheduled for November 5, 2026.
Insider Buying and Selling at Disc Medicine, Inc.
Earlier in the year, Chief Operating Officer Yu Jonathan Yen-Wen disposed of 9,700 shares on June 22, 2026. Chief Legal Officer Rahul Khara bought 851 shares on June 26, 2026, at $14.69 per share for a total of $12,501.19. Khara also sold 1,649 shares on June 29, 2026, at $75.00 under a planned transaction, and purchased another 1,649 shares that same day at $14.69.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the insider sale. BMO Capital maintained an Outperform rating on October 19, 2026, lifting its target to $120.00 from $100.00. Morgan Stanley maintained an Overweight rating on October 20, 2026, raising its target to $92.00 from $90.00. Truist Securities maintained a Buy rating on October 20, 2026, bumping its target to $115.00 from $83.00. Wells Fargo maintained an Overweight rating on the same day, moving its target up to $124.00 from $86.00. Wedbush also maintained an Outperform rating on October 20, 2026, raising its target from $100.00 to $110.00. Overall, the stock carries a strong buy recommendation and a mean price target of $121.00.
About Disc Medicine
Disc Medicine, Inc. is a Watertown, Massachusetts-based clinical-stage biopharmaceutical company focused on discovering and developing treatments for serious hematologic diseases.
Bottom Line
With the latest insider transaction completed under a trading plan, investors are looking ahead to the company's next earnings report on November 5, 2026. The stock continues to trade well above its long-term moving averages while maintaining strong backing from analyst price targets.
Related Filing Alerts
Source: Kevin Bitterman's Form 4 filing on $IRON (Oct 21, 2026). Written by software, not financial advice. How we make alerts